Penumbra Q2 revenue slightly beats estimates, helped by product segment increase
PEN•Growth drivers
- Product segment growth — Embolization and access revenue rose 20% year over year, while thrombectomy revenue increased 12.5%.
- Geographic performance — U.S. revenue grew 17.1% year over year, outpacing international growth of 7.6%.
- Acquisition-related expenses — The company incurred $6.9 million in expenses tied to the pending Boston Scientific acquisition.
Q2 revenue and profit
Penumbra's second-quarter revenue rose 14.9% year over year, slightly beating analyst expectations.
Net income fell to $34.8 million from $45.3 million a year earlier.
The company incurred $6.9 million in acquisition-related expenses amid the pending Boston Scientific deal.
Outlook and analyst view
The company said it will not provide full-year 2026 financial guidance because of the pending acquisition.
The current average analyst rating on the shares is hold, with 3 strong buy or buy, 13 and no or ratings.
